Skip to main content

Research Repository

Advanced Search

All Outputs (51)

Integrated care policy recommendations for complex multisystem long term conditions and long COVID (2024)
Journal Article
van der Feltz-Cornelis, C. M., Sweetman, J., Turk, F., Allsopp, G., Gabbay, M., Khunti, K., Williams, N., Montgomery, H., Heightman, M., Lip, G. Y., Crooks, M. G., Strain, W. D., Loveless, A., Hishmeh, L., Smith, N., & Banerjee, A. (2024). Integrated care policy recommendations for complex multisystem long term conditions and long COVID. Scientific reports, 14(1), Article 13634. https://doi.org/10.1038/s41598-024-64060-1

The importance of integrated care for complex, multiple long term conditions was acknowledged before the COVID pandemic but remained a challenge. The pandemic and consequent development of Long COVID required rapid adaptation of health services to ad... Read More about Integrated care policy recommendations for complex multisystem long term conditions and long COVID.

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD (2024)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Newall, C., Mankowski, M., Crooks, M. G., Singh, D., Chaudhuri, R., Leaker, B., Lunn, K., Reynolds, S., Dudley, S., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2024). Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD. Respiratory Research, 25(1), Article 228. https://doi.org/10.1186/s12931-024-02854-7

Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. This exploratory study aimed to demonst... Read More about Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.

Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective (2023)
Journal Article
Turk, F., Sweetman, J., Allsopp, G., Crooks, M., Cuthbertson, D. J., Gabbay, M., Hishmeh, L., Lip, G. Y., Strain, W. D., Williams, N., Wootton, D., Banerjee, A., & van der Feltz-Cornelis, C. (2023). Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective. Journal of Evidence-Based Medicine, 16(4), 435-437. https://doi.org/10.1111/jebm.12563

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 (2023)
Journal Article
Wilkinson, T., De Soyza, A., Carroll, M., Chalmers, J. D., Crooks, M. G., Griffiths, G., Shankar-Hari, M., Ho, L. P., Horsley, A., Kell, C., Lara, B., Mishra, B., Moate, R., Page, C., Pandya, H., Raw, J., Reid, F., Saralaya, D., Scott, I. C., Siddiqui, S., …on behalf of The ACCORD Collaborative Group. (2023). A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ Open Research, 9(5), Article 00249-2023. https://doi.org/10.1183/23120541.00249-2023

Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving ou... Read More about A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.

Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) (2023)
Journal Article
Alwan, N. A., Clutterbuck, D., Pantelic, M., Hayer, J., Fisher, L., Hishmeh, L., Heightman, M., Allsopp, G., Wootton, D., Khan, A., Hastie, C., Jackson, M., Rayner, C., Brown, D., Parrett, E., Jones, G., Smith, K., Clarke, R., McFarland, S., Gabbay, M., …Cleary, N. (2023). Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways). PLoS ONE, 18(7 July), Article e0284297. https://doi.org/10.1371/journal.pone.0284297

Background and aim Long Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the wor... Read More about Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways).

Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site (2023)
Journal Article
Crooks, M. G., Crowther, L., Cummings, H., Cohen, J., Huang, C., Pitel, L., Pearson, M., Morice, A., Turgoose, J., Faruqi, S., Watt, M., Morris, T., & Xu, Y. (2023). Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site. ERJ Open Research, 9(3), Article 00685-2022. https://doi.org/10.1183/23120541.00685-2022

Aim: Short-acting β2-agonist (SABA) overuse adversely impacts asthma-related outcomes and the environment. The SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) programme aims to reduce SABA overuse through supported implementatio... Read More about Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.

Designing an intervention to help the quitters quit: A qualitative, intervention co-design study (2023)
Journal Article
Dyson, J., Skinner, J., Crick, J., & Crooks, M. G. (2023). Designing an intervention to help the quitters quit: A qualitative, intervention co-design study. PEC Innovation, 2, Article 100141. https://doi.org/10.1016/j.pecinn.2023.100141

Objective: E-cigarettes are increasingly being provided by publicly funded stop smoking services. Our objectives were to understand the challenges and establish the means by which services could best support the use and subsequent discontinuation of... Read More about Designing an intervention to help the quitters quit: A qualitative, intervention co-design study.

Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study (2023)
Journal Article
Killingback, C., Thompson, M., Nettleton, M., Hyde, L., Marshall, P., Shepherdson, J., …Simpson, A. J. (2023). Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study. Disability and Rehabilitation, https://doi.org/10.1080/09638288.2022.2159075

Purpose: The aim of this qualitative study was to explore the views of participants of a group-based, supervised, telerehabilitation programme, following discharge from hospital with Covid-19. This study was part of a single-centre, fast-track (wait-... Read More about Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study.

Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study (2023)
Journal Article
Dennis, A., Cuthbertson, D. J., Wootton, D., Crooks, M., Gabbay, M., Eichert, N., Mouchti, S., Pansini, M., Roca-Fernandez, A., Thomaides-Brears, H., Kelly, M., Robson, M., Hishmeh, L., Attree, E., Heightman, M., Banerjee, R., & Banerjee, A. (2023). Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine, 116(3), 97-112. https://doi.org/10.1177/01410768231154703

Objectives: To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation. Design: Prospective cohort study. Participants: Individuals. Methods: In indiv... Read More about Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study.

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol (2023)
Journal Article
Forshaw, D., Wall, E. C., Prescott, G., Dehbi, H. M., Green, A., Attree, E., Hismeh, L., Strain, W. D., Crooks, M. G., Watkins, C., Robson, C., Banerjee, R., Lorgelly, P., Heightman, M., & Banerjee, A. (2023). STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol. PLoS ONE, 18(2), Article e0272472. https://doi.org/10.1371/journal.pone.0272472

INTRODUCTION: Long COVID (LC), the persistent symptoms ≥12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are ur... Read More about STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol.

Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study (2022)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Mankowski, M., Adzic-Vukicevic, T., Crooks, M. G., Dosanjh, D. P., Kraft, M., Brightling, C. E., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2023). Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study. ERJ Open Research, 9(2), Article 00605-2022. https://doi.org/10.1183/23120541.00605-2022

Background Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, i... Read More about Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.

Group-based pulmonary telerehabilitation is feasible, safe, beneficial and well-received in patients who have been hospitalised with COVID-19 (2022)
Journal Article
Simpson, A. J., Green, A., Nettleton, M., Hyde, L., Shepherdson, J., Killingback, C., …Crooks, M. G. (2023). Group-based pulmonary telerehabilitation is feasible, safe, beneficial and well-received in patients who have been hospitalised with COVID-19. ERJ Open Research, 9(2), Article 00373-2022. https://doi.org/10.1183/23120541.00373-2022

Introduction Coronavirus disease 2019 (COVID-19) has caused worldwide mass hospitalisation. The need for multidisciplinary post-hospitalisation rehabilitation is becoming increasingly apparent, and telerehabilitation has been endorsed. The aim of stu... Read More about Group-based pulmonary telerehabilitation is feasible, safe, beneficial and well-received in patients who have been hospitalised with COVID-19.

STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol (2022)
Journal Article
van der Feltz-Cornelis, C. M., Sweetman, J., Allsopp, G., Attree, E., Crooks, M. G., Cuthbertson, D. J., Forshaw, D., Gabbay, M., Green, A., Heightman, M., Hillman, T., Hishmeh, L., Khunti, K., Lip, G. Y., Lorgelly, P., Montgomery, H., Strain, W. D., Wall, E., Watkins, C., Williams, N., …McAuliffe, S. (2022). STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol. PLoS ONE, 17(11 November), Article e0277936. https://doi.org/10.1371/journal.pone.0277936

Introduction As mortality rates from COVID-19 disease fall, the high prevalence of long-term sequelae (Long COVID) is becoming increasingly widespread, challenging healthcare systems globally. Traditional pathways of care for Long Term Conditions (LT... Read More about STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol.

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms (2022)
Journal Article
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

Background: The interaction between the respiratory and gastrointestinal systems, and the role of the latter in the development of respiratory pathology, has been examined with a focus on gastro-oesophageal reflux disease (GORD). However, little data... Read More about Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms.

Tele-rehabilitation for patients who have been hospitalised with Covid-19: a mixed-methods feasibility trial protocol (2022)
Journal Article
Hyde, L., Simpson, A. J., Nettleton, M., Shepherdson, J., Killingback, C., Marshall, P., …Green, A. (2022). Tele-rehabilitation for patients who have been hospitalised with Covid-19: a mixed-methods feasibility trial protocol. Physical Therapy Reviews, https://doi.org/10.1080/10833196.2022.2028963

Background: Tele-rehabilitation has been proposed as a post-hospitalisation rehabilitation pathway for Covid-19 survivors, however patients’ willingness and ability to engage with this online intervention remains unknown. Objectives: The aim of this... Read More about Tele-rehabilitation for patients who have been hospitalised with Covid-19: a mixed-methods feasibility trial protocol.

Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme (2022)
Journal Article
Wilkinson, A., Maslova, E., Janson, C., Xu, Y., Haughney, J., Quint, J. K., Budgen, N., Menzies-Gow, A., Bell, J., & Crooks, M. G. (2022). Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme. Advances in Therapy, 39, 2270–2280. https://doi.org/10.1007/s12325-022-02076-7

Introduction: Faced with the challenges of climate change, countries are seeking to decarbonise their economies. A greater understanding of what comprises the carbon footprint of care in healthcare systems will identify potential strategies for reduc... Read More about Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme.

Helping the quitters quit: A systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed (2021)
Journal Article
Dyson, J., Bhatnagar, M., Skinner, J., & Crooks, M. (2022). Helping the quitters quit: A systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed. Patient Education and Counseling, 105(6), 1402-1410. https://doi.org/10.1016/j.pec.2021.09.024

Objective: To investigate the barriers and facilitators to and support needed for e-cigarette cessation. Methods: We systematically searched the subject-specific databases MEDLINE, CINAHL complete and psycINFO and the Cochrane database using synonyms... Read More about Helping the quitters quit: A systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed.

Outcomes and characteristics of COVID-19 patients treated with continuous positive airway pressure/high-flow nasal oxygen outside the intensive care setting (2021)
Journal Article
Sykes, D. L., Crooks, M. G., Thu, K. T., Brown, O. I., Tyrer, T. J., Rennardson, J., Littlefield, C., & Faruqi, S. (2021). Outcomes and characteristics of COVID-19 patients treated with continuous positive airway pressure/high-flow nasal oxygen outside the intensive care setting. ERJ Open Research, 7(4), Article 00318-2021. https://doi.org/10.1183/23120541.00318-2021

Background Continuous positive airway pressure (CPAP) and high-flow nasal oxygen (HFNO) have been used to manage hypoxaemic respiratory failure secondary to coronavirus disease 2019 (COVID-19) pneumonia. Limited data are available for patients treate... Read More about Outcomes and characteristics of COVID-19 patients treated with continuous positive airway pressure/high-flow nasal oxygen outside the intensive care setting.

Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations (2021)
Journal Article
Crooks, M. G., den Brinker, A. C., Thackray-Nocera, S., van Dinther, R., Wright, C. E., & Morice, A. H. (2021). Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. Lung, 199(2), 131-137. https://doi.org/10.1007/s00408-021-00435-9

Introduction: Acute exacerbations of COPD (AE-COPD) are a leading cause of health service utilisation and are associated with morbidity and mortality. Identifying the prodrome of AE-COPD by monitoring symptoms and physiological parameters (telemonito... Read More about Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations.